Cargando…

Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration

Duchenne muscular dystrophy (DMD) is a classical monogenic disorder, a model disease for genomic studies and a priority candidate for regenerative medicine and gene therapy. Although the genetic cause of DMD is well known, the molecular pathogenesis of disease and the response to therapy are incompl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roberts, Thomas C., Johansson, Henrik J., McClorey, Graham, Godfrey, Caroline, Blomberg, K. Emelie M., Coursindel, Thibault, Gait, Michael J., Smith, C.I. Edvard, Lehtiö, Janne, EL Andaloussi, Samir, Wood, Matthew J.A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634378/ https://www.ncbi.nlm.nih.gov/pubmed/26385637 http://dx.doi.org/10.1093/hmg/ddv381

Ejemplares similares

Expression Analysis in Multiple Muscle Groups and Serum Reveals Complexity in the MicroRNA Transcriptome of the mdx Mouse with Implications for Therapy
por: Roberts, Thomas C, et al.
Publicado: (2012)

mRNA and microRNA transcriptomics analyses in a murine model of dystrophin loss and therapeutic restoration
por: Roberts, Thomas C., et al.
Publicado: (2015)

Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA
por: Järver, Peter, et al.
Publicado: (2012)

Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy
por: Malerba, Alberto, et al.
Publicado: (2012)

Cells release subpopulations of exosomes with distinct molecular and biological properties
por: Willms, Eduard, et al.
Publicado: (2016)

Peptide Nanoparticle Delivery of Charge-Neutral Splice-Switching Morpholino Oligonucleotides
por: Järver, Peter, et al.
Publicado: (2015)

Exon skipping induces uniform dystrophin rescue with dose-dependent restoration of serum miRNA biomarkers and muscle biophysical properties
por: Chwalenia, Katarzyna, et al.
Publicado: (2022)

Small RNA-Mediated Epigenetic Myostatin Silencing
por: Roberts, Thomas C, et al.
Publicado: (2012)

Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy
por: Blain, Alison M., et al.
Publicado: (2018)

Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment
por: Gait, Michael J., et al.
Publicado: (2019)

Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy
por: Shabanpoor, Fazel, et al.
Publicado: (2015)

Dystrophin involvement in peripheral circadian SRF signalling
por: Betts, Corinne A, et al.
Publicado: (2021)

Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment
por: Betts, Corinne A, et al.
Publicado: (2019)

Correlating In Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified Oligonucleotides
por: Hammond, Suzan M, et al.
Publicado: (2014)

Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment
por: Betts, Corinne, et al.
Publicado: (2012)

Splice-Switching Therapy for Spinal Muscular Atrophy
por: Meijboom, Katharina E., et al.
Publicado: (2017)

Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology
por: van Westering, Tirsa L.E., et al.
Publicado: (2019)

Splice-Correction Strategies for Treatment of X-Linked Agammaglobulinemia
por: Bestas, Burcu, et al.
Publicado: (2015)

Modulating the Expression of Disease Genes with RNA-Based Therapy
por: Wood, Matthew, et al.
Publicado: (2007)

Covalently attached intercalators restore duplex stability and splice-switching activity to triazole-modified oligonucleotides
por: Dysko, Anna, et al.
Publicado: (2022)

Cell-Penetrating Peptides to Enhance Delivery of Oligonucleotide-Based Therapeutics
por: McClorey, Graham, et al.
Publicado: (2018)

Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells
por: Lehto, Taavi, et al.
Publicado: (2014)

Extracellular microRNAs are dynamic non-vesicular biomarkers of muscle turnover
por: Roberts, Thomas C., et al.
Publicado: (2013)

Modulation of Pro-Inflammatory IL-6 Trans-Signaling Axis by Splice Switching Oligonucleotides as a Therapeutic Modality in Inflammation
por: Gupta, Dhanu, et al.
Publicado: (2023)

Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics
por: Coenen-Stass, Anna M. L., et al.
Publicado: (2015)

Corrigendum: Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics
por: Coenen-Stass, Anna M. L., et al.
Publicado: (2016)

Fine Tuning of Phosphorothioate Inclusion in 2′-O-Methyl Oligonucleotides Contributes to Specific Cell Targeting for Splice-Switching Modulation
por: Aoki, Yoshitsugu, et al.
Publicado: (2021)

Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice
por: Betts, Corinne A., et al.
Publicado: (2015)

Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy
por: Betts, Corinne A., et al.
Publicado: (2015)

Restoration of dystrophin expression using the Sleeping Beauty transposon
por: Muses, Sofia, et al.
Publicado: (2012)

Immortalized Canine Dystrophic Myoblast Cell Lines for Development of Peptide-Conjugated Splice-Switching Oligonucleotides
por: Tone, Yuichiro, et al.
Publicado: (2021)

Effective Exon Skipping and Dystrophin Restoration by 2′-O-Methoxyethyl Antisense Oligonucleotide in Dystrophin-Deficient Mice
por: Yang, Lu, et al.
Publicado: (2013)

Serum-free culture alters the quantity and protein composition of neuroblastoma-derived extracellular vesicles
por: Li, Jinghuan, et al.
Publicado: (2015)

Effective Dystrophin Restoration by a Novel Muscle-Homing Peptide-Morpholino Conjugate in Dystrophin-Deficient mdx Mice
por: Gao, Xianjun, et al.
Publicado: (2020)

Good news for the mdx mouse community: Improved dystrophin restoration after skipping mouse dystrophin exon 23
por: Aartsma-Rus, Annemieke
Publicado: (2022)

Non-uniform dystrophin re-expression after CRISPR-mediated exon excision in the dystrophin/utrophin double-knockout mouse model of DMD
por: Hanson, Britt, et al.
Publicado: (2022)

Micro-minicircle Gene Therapy: Implications of Size on Fermentation, Complexation, Shearing Resistance, and Expression
por: Stenler, Sofia, et al.
Publicado: (2014)

Dystrophin myonuclear domain restoration governs treatment efficacy in dystrophic muscle
por: Morin, Adrien, et al.
Publicado: (2023)

CRISPR/Cas9‐Based Dystrophin Restoration Reveals a Novel Role for Dystrophin in Bioenergetics and Stress Resistance of Muscle Progenitors
por: Matre, Polina R., et al.
Publicado: (2019)

Restoration of brain dystrophin using tricyclo-DNA ASOs restores neurobehavioral deficits in DMD mice
por: Karuppasamy, Muthukumar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2onreunviijlj26d83n67lkhlb